Tuberculosis of the central nervous system

Clinical Tuberculosis, Fifth Edition

Volumn , Issue , 2014, Pages 151-166

  Thwaites, Guy ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84921021255     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b16604     Document Type: Chapter

References (102)

1. Farer LS, Lowell AM, and Meador MP. Extrapulmonary tuberculosis in the United States. Am J Epidemiol 1979;109(2):205-17.
2. de March-Ayuela P. Trend in tuberculous meningitis in Barcelona in children aged 0-4 years: correlation with the annual risk of tuberculous infection. Tuber Lung Dis 1994;75(6):423-8.
3. Zhang LX, Tu DH, and Enarson DA. The impact of directly-observed treatment on the epidemiology of tuberculosis in Beijing. Int J Tuberc Lung Dis 2000;4(10):904-10.
4. Keane J. TNF-blocking agents and tuberculosis: new drugs illu-minate an old topic. Rheumatology (Oxford) 2005;44(6):714-20.
5. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A prospective study of the risk of tuber-culosis among intravenous drug users with human immunode-ficiency virus infection. N Eng J Med 1989;320(9):545-50.
6. Bishburg E, Sunderam G, Reichman LB, and Kapila R. Central nervous system tuberculosis with the acquired immu-nodeficiency syndrome and its related complex. Ann Intern Med 1986;105(2):210-13.
7. Nicol MP and Wilkinson RJ. The clinical consequences of strain diversity in Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg 2008;102(10):955-65.
8. Gagneux S and Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 2007;7(5):328-37.
9. Caws M, Thwaites G, Dunstan S, Hawn TR, Lan NT, Thuong NT, et al. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog 2008;4(3):e1000034.
10. Krishnan N, Malaga W, Constant P, Caws M, Tran TH, Salmons J, et al. Mycobacterium tuberculosis lineage influences innate immune response and virulence and is associated with distinct cell envelope lipid profiles. PLoS One 2011;6(9):e23870.
11. Hawn TR, Dunstan SJ, Thwaites GE, Simmons CP, Thuong NT, Lan NT, et al. A polymorphism in Toll-interleukin 1 receptor domain containing adaptor protein is associated with susceptibil-ity to meningeal tuberculosis. J Infect Dis 2006;194(8):1127-34.
12. Thuong NT, Hawn TR, Thwaites GE, Chau TT, Lan NT, Quy HT, et al. A polymorphism in human TLR2 is associated with increased susceptibility to tuberculous meningitis. Genes Immun 2007;8(5):422-8.
13. Rich AR and McCordock HA. The pathogenesis of tubercu-lous meningitis. Bull Johns Hopkins Hosp 1933;52:5-37.
14. Flynn JL, Chan J, and Lin PL. Macrophages and control of granulomatous inflammation in tuberculosis. Mucosal Immunol 2011;4(3):271-8.
15. Thwaites GE, Macmullen-Price J, Tran TH, Pham PM, Nguyen TD, Simmons CP, et al. Serial MRI to determine the effect of dexamethasone on the cerebral pathology of tuber-culous meningitis: an observational study. Lancet Neurol 2007;6(3):230-6.
16. Thwaites GE and Tran TH. Tuberculous meningitis: many questions, too few answers. Lancet Neurol 2005;4(3):160-70.
17. Hsieh FY, Chia LG, Shen WC. Locations of infarctions in cerebral tuberculosis. Neuroradiology. 1992;34(3):197-9.
18. Thwaites GE and Schoeman JF. Update on tuberculosis of the central nervous system: pathogenesis, diagnosis, and treat-ment. Clin Chest Med 2009;30(4):745-54, ix.
19. Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, and Innes J. British Infection Society guidelines for the diag-nosis and treatment of tuberculosis of the central nervous sys-tem in adults and children. J Infect 2009;59(3):167-87.
20. Kent SJ, Crowe SM, Yung A, Lucas CR, and Mijch AM. Tuberculous meningitis: a 30-year review. Clin Infect Dis 1993;17(6):987-94.
21. Dastur HM. Diagnosis and neurosurgical treatment of tuber-culous disease of the CNS. Neurosurg Rev 1983;6(3):111-17.
22. Chotmongkol V, Kitkuandee A, and Limpawattana P. Tuberculous radiculomyelitis (arachnoiditis) associated with tuberculous meningitis. Southeast Asian J Trop Med Public Health 2005;36(3):722-4.
23. Nicolls DJ, King M, Holland D, Bala J, and del Rio C. Intracranial tuberculomas developing while on therapy for pul-monary tuberculosis. Lancet Infect Dis 2005;5(12):795-801.
24. Bayindir C, Mete O, and Bilgic B. Retrospective study of 23 pathologically proven cases of central nervous system tuber-culomas. Clin Neurol Neurosurg 2006;108(4):353-7.
25. Rajeswari R, Sivasubramanian S, Balambal R, Parthasarathy R, Ranjani R, Santha T, et al. A controlled clinical trial of short-course chemotherapy for tuberculoma of the brain. Tuber Lung Dis 1995;76(4):311-17.
26. Martinez-Vazquez C, Bordon J, Rodriguez-Gonzalez A, de la Fuente-Aguado J, Sopena B, Gallego-Rivera A, et al. Cerebral tuberculoma-a comparative study in patients with and with-out HIV infection. Infection 1995;23(3):149-53.
27. Kumar R, Singh SN, and Kohli N. A diagnostic rule for tuber-culous meningitis. Arch Dis Child 1999;81(3):221-4.
28. Thwaites GE, Chau TT, Stepniewska K, Phu NH, Chuong LV, Sinh DX, et al. Diagnosis of adult tuberculous men-ingitis by use of clinical and laboratory features. Lancet 2002;360(9342):1287-92.
29. Youssef FG, Afifi SA, Azab AM, Wasfy MM, Abdel-Aziz KM, Parker TM, et al. Differentiation of tuberculous men-ingitis from acute bacterial meningitis using simple clini-cal and laboratory parameters. Diagn Microbiol Infect Dis 2006;55(4):275-8.
30. Foerster BR, Thurnher MM, Malani PN, Petrou M, Carets-Zumelzu F, and Sundgren PC. Intracranial infections: clinical and imaging characteristics. Acta Radiol 2007;48(8):875-93.
31. Ozates M, Kemaloglu S, Gurkan F, Ozkan U, Hosoglu S, and Simsek MM. CT of the brain in tuberculous meningitis. A review of 289 patients. Acta Radiol 2000;41(1):13-17.
32. Andronikou S, Smith B, Hatherhill M, Douis H, and Wilmshurst J. Definitive neuroradiological diagnostic features of tubercu-lous meningitis in children. Pediatr Radiol 2004;34(11):876-85.
33. Koh SB, Kim BJ, Park MH, Yu SW, Park KW, and Lee DH. Clinical and laboratory characteristics of cerebral infarction in tuberculous meningitis: a comparative study. J Clin Neurosci 2007;14(11):1073-7.
34. du Plessis J, Andronikou S, Wieselthaler N, Theron S, George R, and Mapukata A. CT features of tuberculous intracranial abscesses in children. Pediatr Radiol 2007;37(2):167-72.
35. Garg RK, Desai P, Kar M, and Kar AM. Multiple ring enhanc-ing brain lesions on computed tomography: an Indian per-spective. J Neurol Sci 2008;266(1-2):92-6.
36. Kingsley PB, Shah TC, and Woldenberg R. Identification of diffuse and focal brain lesions by clinical magnetic resonance spectroscopy. NMR Biomed 2006;19(4):435-62.
37. Pretell EJ, Martinot C Jr, Garcia HH, Alvarado M, Bustos JA, and Martinot C. Differential diagnosis between cerebral tuberculosis and neurocysticercosis by magnetic resonance spectroscopy. J Comput Assist Tomogr 2005;29(1):112-14.
38. Thwaites GE, Simmons CP, Than Ha Quyen N, Thi Hong Chau T, Phuong Mai P, Thi Dung N, et al. Pathophysiology and prognosis in Vietnamese adults with tuberculous meningitis. J Infect Dis 2003;188(8):1105-15.
39. Stewart SM. The bacteriological diagnosis of tuberculous meningitis. J Clin Pathol 1953;6:241-2.
40. Thwaites GE, Chau TT, and Farrar JJ. Improving the bacterio-logical diagnosis of tuberculous meningitis. J Clin Microbiol 2004;42(1):378-9.
41. Baker CA, Cartwright CP, Williams DN, Nelson SM, and Peterson PK. Early detection of central nervous system tuberculosis with the gen-probe nucleic acid amplifica-tion assay: utility in an inner city hospital. Clin Infect Dis 2002;35(3):339-42.
42. Rajshekhar V, Abraham J, and Chandy MJ. Avoiding empiric therapy for brain masses in Indian patients using CT-guided stereotaxy. Br J Neurosurg 1990;4(5):391-6.
43. Sumi MG, Mathai A, Sheela R, Radhakrishnan NS, Radhakrishnan VV, Indhulekshmy R, et al. Diagnostic util-ity of polymerase chain reaction and immunohistochemical techniques for the laboratory diagnosis of intracranial tuber-culoma. Clin Neuropathol 2001;20(4):176-80.
44. Pai M, Flores LL, Pai N, Hubbard A, Riley LW, and Colford JM. Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2003;3(10):633-43.
45. Donald PR, Victor TC, Jordaan AM, Schoeman JF, and van Helden PD. Polymerase chain reaction in the diagnosis of tuberculous meningitis. Scand J Infect Dis 1993;25(5):613-17.
46. Thwaites GE, Caws M, Chau TT, Dung NT, Campbell JI, Phu NH, et al. Comparison of conventional bacteriology with nucleic acid amplification (amplified mycobacterium direct test) for diagnosis of tuberculous meningitis before and after inception of antituberculosis chemotherapy. J Clin Microbiol 2004;42(3):996-1002.
47. Takahashi T and Nakayama T. Novel technique of quantitative nested real-time PCR assay for Mycobacterium tuberculosis DNA. J Clin Microbiol 2006;44(3):1029-39.
48. Takahashi T, Tamura M, Asami Y, Kitamura E, Saito K, Suzuki T, et al. Novel “wide range” quantitative nested real-time PCR assay for Mycobacterium tuberculosis DNA-development and methodology. J Clin Microbiol 2008;46:1698-707.
49. Lawn SD and Nicol MP. Xpert(R) MTB/RIF assay: develop-ment, evaluation and implementation of a new rapid molec-ular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 2011;6(9):1067-82.
50. Vadwai V, Boehme C, Nabeta P, Shetty A, Alland D, and Rodrigues C. Xpert MTB/RIF: a new pillar in diag-nosis of extrapulmonary tuberculosis? J Clin Microbiol 2011;49(7):2540-5.
51. Metcalfe JZ, Everett CK, Steingart KR, Cattamanchi A, Huang L, Hopewell PC, et al. Interferon-gamma release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis 2011;204(Suppl 4):S1120-9.
52. Patel VB, Singh R, Connolly C, Coovadia Y, Peer AK, Parag P, et al. Cerebrospinal T-cell responses aid in the diagnosis of tuberculous meningitis in a human immunodeficiency virus- and tuberculosis-endemic population. Am J Respir Crit Care Med 2010;182(4):569-77.
53. Kim SH, Cho OH, Park SJ, Lee EM, Kim MN, Lee SO, et al. Rapid diagnosis of tuberculous meningitis by T cell-based assays on peripheral blood and cerebrospinal fluid mononu-clear cells. Clin Infect Dis 2010;50(10):1349-58.
54. Ellard GA, Humphries MJ, and Allen BW. Cerebrospinal fluid drug concentrations and the treatment of tuberculous menin-gitis. Am Rev Respir Dis 1993;148(3):650-5.
55. Thwaites GE, Lan NT, Dung NH, Quy HT, Oanh DT, Thoa NT, et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis 2005;192(1):79-88.
56. Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven AJ, et al. Intensified regimen containing rifam-picin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013;13:27-35.
57. Ellard GA, Humphries MJ, Gabriel M, and Teoh R. Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis. Br Med J (Clin Res Ed) 1987;294(6567):284-5.
58. WHO (World Health Organization). Global tuberculosis con-trol: WHO report 2011. Geneva: WHO, 2011.
59. Donald PR, Maher D, Maritz JS, and Qazi S. Ethambutol dos-age for the treatment of children: literature review and recom-mendations. Int J Tuberc Lung Dis 2006;10(12):1318-30.
60. Donald PR and Seifart HI. Cerebrospinal fluid concentra-tions of ethionamide in children with tuberculous meningitis. J Pediatr 1989;115(3):483-6.
61. Alffenaar JW, de Vries PM, Luijckx GJ, van Soolingen D, van der Werf TS, and van Altena R. Plasma and CSF pharmacoki-netics of moxifloxacin in a patient with tuberculous meningi-tis. Antimicrob Agents Chemother 2008;52:2293-5.
62. Thwaites GE, Bhavnani SM, Chau TT, Hammel JP, Torok ME, Van Wart SA, et al. Randomized pharmacokinetic and phar-macodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother 2011;55(7):3244-53.
63. Donald PR, Schoeman JF, Van Zyl LE, De Villiers JN, Pretorius M, and Springer P. Intensive short course chemo-therapy in the management of tuberculous meningitis. Int J Tuberc Lung Dis 1998;2(9):704-11.
64. Humphries M. The management of tuberculous meningitis. Thorax 1992;47(8):577-81.
65. Kaojarern S, Supmonchai K, Phuapradit P, Mokkhavesa C, and Krittiyanunt S. Effect of steroids on cerebrospinal fluid penetration of antituberculous drugs in tuberculous meningi-tis. Clin Pharmacol Ther 1991;49(1):6-12.
66. Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007;51(8):2994-6.
67. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, et al. Dexamethasone for the treatment of tuber-culous meningitis in adolescents and adults. N Eng J Med 2004;351(17):1741-51.
68. van Loenhout-Rooyackers JH, Keyser A, Laheij RJ, Verbeek AL, and van der Meer JW. Tuberculous meningitis: is a 6-month treatment regimen sufficient? Int J Tuberc Lung Dis 2001;5(11):1028-35.
69. American Thoracic Society (ATS), CDC, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003;52(RR-11):1-77.
70. Abate G, Hoffner SE, Thomsen VO, and Miorner H. Characterization of isoniazid-resistant strains of Mycobacterium tuberculosis on the basis of phenotypic properties and mutations in katG. Eur J Clin Microbiol Infect Dis 2001;20(5):329-33.
71. Vinnard C, Winston CA, Wileyto EP, Macgregor RR, and Bisson GP. Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study. BMJ 2010;341:c4451.
72. WHO (World Health Organization). The treatment of tubercu-losis guidelines, 4th edn. Geneva: WHO, 2010.
73. WHO (World Health Organization). Guidelines for the prag-matic management of drug-resistant tuberculosis. Geneva: WHO, 2006.
74. Holdiness MR. Cerebrospinal fluid pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1985;10(6):532-4.
75. Prasad K and Singh MB. Corticosteroids for manag-ing tuberculous meningitis. Cochrane Database Syst Rev 2008;(1):CD002244.
76. Torok ME, Nguyen DB, Tran TH, Nguyen TB, Thwaites GE, Hoang TQ, et al. Dexamethasone and long-term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One 2011;6(12):e27821.
77. Malhotra HS, Garg RK, Singh MK, Agarwal A, and Verma R. Corticosteroids (dexamethasone vs. intravenous methylpred-nisolone) in patients with tuberculous meningitis. Ann Trop Med Parasitol 2009;103(7):625-34.
78. Schoeman JF, Van Zyl LE, Laubscher JA, and Donald PR. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics 1997;99(2):226-31.
79. Hristea A, Constantinescu RV, Exergian F, Arama V, Besleaga M, and Tanasescu R. Paraplegia due to non-osseous spinal tuberculosis: report of three cases and review of the literature. Int J Infect Dis 2008;12:425-9.
80. Green JA, Tran CT, Farrar JJ, Nguyen MT, Nguyen PH, Dinh SX, et al. Dexamethasone, cerebrospinal fluid matrix metalloproteinase concentrations and clinical outcomes in tuberculous meningitis. PLoS One 2009;4(9):e7277.
81. Simmons CP, Thwaites GE, Quyen NT, Chau TT, Mai PP, Dung NT, et al. The clinical benefit of adjunctive dexametha-sone in tuberculous meningitis is not associated with mea-surable attenuation of peripheral or local immune responses. J Immunol 2005;175(1):579-90.
82. Tobin DM, Vary JC Jr, Ray JP, Walsh GS, Dunstan SJ, Bang ND, et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 2010;140(5):717-30.
83. Tobin DM, Roca FJ, Oh SF, McFarland R, Vickery TW, Ray JP, et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012;148(3):434-46.
84. Roberts MT, Mendelson M, Meyer P, Carmichael A, and Lever AM. The use of thalidomide in the treatment of intra-cranial tuberculomas in adults: two case reports. J Infect 2003;47(3):251-5.
85. Schoeman JF, Ravenscroft A, and Hartzenberg HB. Possible role of adjunctive thalidomide therapy in the resolution of a massive intracranial tuberculous abscess. Childs Nerv Syst 2001;17(6):370-2.
86. Schoeman JF, Fieggen G, Seller N, Mendelson M, and Hartzenberg B. Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases. J Child Neurol 2006;21(4):301-8.
87. Schoeman JF, Springer P, van Rensburg AJ, Swanevelder S, Hanekom WA, Haslett PA, et al. Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a ran-domized study. J Child Neurol 2004;19(4):250-7.
88. Lee HS, Lee Y, Lee SO, Choi SH, Kim YS, Woo JH, et al. Adalimumab treatment may replace or enhance the activity of steroids in steroid-refractory tuberculous meningitis. J Infect Chemother 2012;18(4):555-7.
89. Jorge JH, Graciela C, Pablo AP, and Luis SH. A life-threaten-ing central nervous system-tuberculosis inflammatory reaction nonresponsive to corticosteroids and successfully controlled by infliximab in a young patient with a variant of juvenile idiopathic arthritis. J Clin Rheumatol 2012;18(4):189-91.
90. Schoeman J, Donald P, van Zyl L, Keet M, and Wait J. Tuberculous hydrocephalus: comparison of different treat-ments with regard to ICP, ventricular size and clinical out-come. Dev Med Child Neurol 1991;33(5):396-405.
91. Lamprecht D, Schoeman J, Donald P, and Hartzenberg H. Ventriculoperitoneal shunting in childhood tuberculous men-ingitis. Br J Neurosurg 2001;15(2):119-25.
92. Agrawal D, Gupta A, and Mehta VS. Role of shunt surgery in pediatric tubercular meningitis with hydrocephalus. Indian Pediatr 2005;42(3):245-50.
93. Mathew JM, Rajshekhar V, and Chandy MJ. Shunt surgery in poor grade patients with tuberculous meningitis and hydro-cephalus: effects of response to external ventricular drainage and other variables on long term outcome. J Neurol Neurosurg Psychiatry 1998;65(1):115-18.
94. Figaji AA, Fieggen AG, and Peter JC. Endoscopy for tubercu-lous hydrocephalus. Childs Nerv Syst 2007;23(1):79-84.
95. Jha D, Khatri P, Choudhary A, Sethi R, and Kumar S. Endoscopic third ventriculostomy in prepontine-suprasellar tuberculoma with tuberculous meningitis hydrocephalus: a case report. Pediatr Neurosurg 2007;43(1):42-6.
96. Kumar R, Pandey CK, Bose N, and Sahay S. Tuberculous brain abscess: clinical presentation, pathophysiology and treatment (in children). Childs Nerv Syst 2002;18(3-4):118-23.
97. Jain AK and Dhammi IK. Tuberculosis of the spine: a review. Clin Orthop Relat Res 2007;460:39-49.
98. Turgut M. Spinal tuberculosis (Pott’s disease): its clinical pre-sentation, surgical management, and outcome. A survey study on 694 patients. Neurosurg Rev 2001;24(1):8-13.
99. Muthukumar N, Venkatesh G, Senthilbabu S, and Rajbaskar R. Surgery for intramedullary tuberculoma of the spinal cord: report of 2 cases. Surg Neurol 2006;66(1):69-74; discussion.
100. NICE. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: Royal College of Physicians, 2006.
101. Trunz BB, Fine P, and Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tubercu-losis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006;367(9517):1173-80.
102. Brewer TF. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 2000;31(Suppl 3):S64-7.